Dyadic International’s (DYAI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Dyadic International (NASDAQ:DYAI) in a report issued on Thursday morning,Benzinga reports. The firm currently has a $6.00 price objective on the biotechnology company’s stock.

Dyadic International Stock Down 0.9 %

DYAI opened at $1.13 on Thursday. Dyadic International has a 12 month low of $0.93 and a 12 month high of $2.67. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.39. The stock has a market cap of $33.43 million, a P/E ratio of -4.91 and a beta of 0.72. The stock’s 50 day moving average price is $1.12 and its 200 day moving average price is $1.42.

Dyadic International (NASDAQ:DYAI) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.06. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. The firm had revenue of $1.96 million for the quarter, compared to analysts’ expectations of $1.05 million. During the same period last year, the firm earned ($0.06) EPS. As a group, research analysts predict that Dyadic International will post -0.28 earnings per share for the current year.

Institutional Trading of Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. boosted its holdings in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 847,301 shares of the biotechnology company’s stock after acquiring an additional 21,000 shares during the quarter. Chapin Davis Inc. owned 2.90% of Dyadic International worth $1,254,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.